We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Novo Nordisk (NVO) Suffers a Larger Drop Than the General Market: Key Insights
Read MoreHide Full Article
In the latest trading session, Novo Nordisk (NVO - Free Report) closed at $83.34, marking a -1.99% move from the previous day. This move lagged the S&P 500's daily loss of 1.11%. Elsewhere, the Dow saw a downswing of 0.42%, while the tech-heavy Nasdaq depreciated by 1.89%.
Shares of the drugmaker witnessed a loss of 23.45% over the previous month, trailing the performance of the Medical sector with its loss of 6.22% and the S&P 500's loss of 1.7%.
Investors will be eagerly watching for the performance of Novo Nordisk in its upcoming earnings disclosure. The company's upcoming EPS is projected at $0.85, signifying a 19.72% increase compared to the same quarter of the previous year. Meanwhile, our latest consensus estimate is calling for revenue of $11.34 billion, up 19.23% from the prior-year quarter.
Investors should also pay attention to any latest changes in analyst estimates for Novo Nordisk. These latest adjustments often mirror the shifting dynamics of short-term business patterns. Therefore, positive revisions in estimates convey analysts' confidence in the company's business performance and profit potential.
Based on our research, we believe these estimate revisions are directly related to near-team stock moves. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system.
The Zacks Rank system, running from #1 (Strong Buy) to #5 (Strong Sell), holds an admirable track record of superior performance, independently audited, with #1 stocks contributing an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has witnessed a 3.06% decrease. Currently, Novo Nordisk is carrying a Zacks Rank of #4 (Sell).
In the context of valuation, Novo Nordisk is at present trading with a Forward P/E ratio of 21.89. This signifies a premium in comparison to the average Forward P/E of 12.34 for its industry.
We can also see that NVO currently has a PEG ratio of 0.91. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. The Large Cap Pharmaceuticals industry had an average PEG ratio of 1.26 as trading concluded yesterday.
The Large Cap Pharmaceuticals industry is part of the Medical sector. At present, this industry carries a Zacks Industry Rank of 191, placing it within the bottom 24% of over 250 industries.
The Zacks Industry Rank assesses the vigor of our specific industry groups by computing the average Zacks Rank of the individual stocks incorporated in the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Remember to apply Zacks.com to follow these and more stock-moving metrics during the upcoming trading sessions.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Novo Nordisk (NVO) Suffers a Larger Drop Than the General Market: Key Insights
In the latest trading session, Novo Nordisk (NVO - Free Report) closed at $83.34, marking a -1.99% move from the previous day. This move lagged the S&P 500's daily loss of 1.11%. Elsewhere, the Dow saw a downswing of 0.42%, while the tech-heavy Nasdaq depreciated by 1.89%.
Shares of the drugmaker witnessed a loss of 23.45% over the previous month, trailing the performance of the Medical sector with its loss of 6.22% and the S&P 500's loss of 1.7%.
Investors will be eagerly watching for the performance of Novo Nordisk in its upcoming earnings disclosure. The company's upcoming EPS is projected at $0.85, signifying a 19.72% increase compared to the same quarter of the previous year. Meanwhile, our latest consensus estimate is calling for revenue of $11.34 billion, up 19.23% from the prior-year quarter.
Investors should also pay attention to any latest changes in analyst estimates for Novo Nordisk. These latest adjustments often mirror the shifting dynamics of short-term business patterns. Therefore, positive revisions in estimates convey analysts' confidence in the company's business performance and profit potential.
Based on our research, we believe these estimate revisions are directly related to near-team stock moves. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system.
The Zacks Rank system, running from #1 (Strong Buy) to #5 (Strong Sell), holds an admirable track record of superior performance, independently audited, with #1 stocks contributing an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has witnessed a 3.06% decrease. Currently, Novo Nordisk is carrying a Zacks Rank of #4 (Sell).
In the context of valuation, Novo Nordisk is at present trading with a Forward P/E ratio of 21.89. This signifies a premium in comparison to the average Forward P/E of 12.34 for its industry.
We can also see that NVO currently has a PEG ratio of 0.91. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. The Large Cap Pharmaceuticals industry had an average PEG ratio of 1.26 as trading concluded yesterday.
The Large Cap Pharmaceuticals industry is part of the Medical sector. At present, this industry carries a Zacks Industry Rank of 191, placing it within the bottom 24% of over 250 industries.
The Zacks Industry Rank assesses the vigor of our specific industry groups by computing the average Zacks Rank of the individual stocks incorporated in the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Remember to apply Zacks.com to follow these and more stock-moving metrics during the upcoming trading sessions.